Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - L1 - BRAF wild, ... vs. anti-PD-(L)1, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMspire-170, 2020 (REV) 0.94 [0.62; 1.44]
0.94 [0.62 ; 1.44 ] IMspire-170, 2020 (REV) 1 0% 446 NA not evaluable progression or deaths (PFS)detailed results IMspire-170, 2020 (REV) 0.87 [0.67; 1.14]
0.87 [0.67 ; 1.14 ] IMspire-170, 2020 (REV) 1 0% 446 NA not evaluable DCRdetailed results IMspire-170, 2020 (REV) 1.09 [0.75; 1.59]
1.09 [0.75 ; 1.59 ] IMspire-170, 2020 (REV) 1 0% 446 NA not evaluable objective responses (ORR)detailed results IMspire-170, 2020 (REV) 1.30 [0.85; 1.99]
1.30 [0.85 ; 1.99 ] IMspire-170, 2020 (REV) 1 0% 446 NA not evaluable AE (any grade)detailed results IMspire-170, 2020 (REV) 0.07 [0.02; 0.30]
0.07 [0.02 ; 0.30 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.25 [0.17; 0.37]
0.25 [0.17 ; 0.37 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable AE leading to death (grade 5)detailed results IMspire-170, 2020 (REV) 0.72 [0.23; 2.31]
0.72 [0.23 ; 2.31 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 1.02 [0.14; 7.30]
1.02 [0.14 ; 7.30 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Anaemia AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.57 [0.17; 1.99]
0.57 [0.17 ; 1.99 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 1.02 [0.02; 51.57]
1.02 [0.02 ; 51.57 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Asthenia AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.57 [0.17; 1.99]
0.57 [0.17 ; 1.99 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Constipation AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 1.02 [0.02; 51.57]
1.02 [0.02 ; 51.57 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.51 [0.02; 15.23]
0.51 [0.02 ; 15.23 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Dermatitis acneiform AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.04 [0.00; 0.75]
0.04 [0.00 ; 0.75 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.23 [0.07; 0.68]
0.23 [0.07 ; 0.68 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Fatigue AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.61 [0.14; 2.57]
0.61 [0.14 ; 2.57 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Headache AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.51 [0.02; 15.23]
0.51 [0.02 ; 15.23 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Hypertension AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.57 [0.23; 1.38]
0.57 [0.23 ; 1.38 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Increase AST AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.33 [0.07; 1.67]
0.33 [0.07 ; 1.67 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.50 [0.12; 2.03]
0.50 [0.12 ; 2.03 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Increased Lipase Level AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.50 [0.15; 1.69]
0.50 [0.15 ; 1.69 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Nausea AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.10 [0.01; 1.84]
0.10 [0.01 ; 1.84 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 1.02 [0.06; 16.39]
1.02 [0.06 ; 16.39 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Pruritus AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 1.02 [0.02; 51.57]
1.02 [0.02 ; 51.57 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.17 [0.02; 1.39]
0.17 [0.02 ; 1.39 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Rash AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.13 [0.03; 0.57]
0.13 [0.03 ; 0.57 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.13 [0.01; 2.38]
0.13 [0.01 ; 2.38 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Sepsis AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.08 [0.00; 1.49]
0.08 [0.00 ; 1.49 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable Vomiting AE (grade 3-4)detailed results IMspire-170, 2020 (REV) 0.40 [0.08; 2.09]
0.40 [0.08 ; 2.09 ] IMspire-170, 2020 (REV) 1 0% 436 NA not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 13:33 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 128
- treatments: 359